Strategic Management of Nanotechnology Innovation: Bridging Scientific Discovery and Commercial Value Across Industries

Nanotechnology allows us to manipulate material properties at the nanoscale for performance levels we have never seen before. It is changing entire industries. Yet, there is a stubborn gap between what scientists discover and what actually makes it to the market. When nanotechnology initiatives fail—and they often do—it is usually not because the science is bad. The technology works. The failure comes from poor strategic management, business models that do not fit, or governance structures that are simply too weak to handle the complexity. This paper looks at how strategic management practices act as a bridge across the science–business divide in nanotechnology-driven innovation. We draw on qualitative comparative case studies. Specifically, we look at sectors ranging from healthcare and energy to electronics. The analysis focuses on how organizations align R&D with their broader strategic objectives or how they manage interdisciplinary collaboration. We also look at how they protect intellectual property. Crucially, the study examines how firms embed risk governance directly into their innovation processes rather than treating it as an afterthought. By using thematic coding of secondary data—pulled from both peer-reviewed literature and industry cases—we identify specific patterns. These cover commercialization pathways, leadership approaches, and ecosystem strategies. What the findings show is clear. Successful nanotechnology commercialization relies on a difficult balance: maintaining scientific rigor while remaining responsive to the market. This requires adaptive business models. It requires ethical governance. Finally, the study proposes an integrated strategic management framework to help firms use nanotechnology responsibly to achieve a sustainable competitive advantage.